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Background: Increasing interest has been devoted to the expression and possible role of sex hormone receptors
in gastric cancer, but most of these findings are controversial. In the present study, the expression profile of sex
hormone receptors in gastric cancer and their clinicopathological and prognostic value were determined in a
large Chinese cohort.
Methods: The mRNA and protein expression of estrogen receptor alpha (ERα), estrogen receptor beta (ERβ),
progesterone receptor (PR), and androgen receptor (AR) in primary gastric tumors and corresponding adjacent
normal tissues from 60 and 866 Chinese gastric cancer patients was detected by real-time quantitative PCR and
immunohistochemistry method, respectively. The expression profile of the four receptors was compared and their
associations with clinicopathological characteristics were assessed by using Chi-square test. The prognostic value
of the four receptors in gastric cancer was evaluated by using univariate and multivariate Cox regression analysis.
Results: The presence of ERα, ERβ, PR, and AR in both gastric tumors and normal tissues was confirmed but their
expression levels were extremely low except for the predominance of ERβ. The four receptors were expressed
independently and showed a decreased expression pattern in gastric tumors compared to adjacent normal tissues.
The positive expression of the four receptors all correlated with high tumor grade and intestinal type, and ERα
and AR were also associated with early TNM stage and thereby a favorable outcome. However, ERα and AR were
not independent prognostic factors for gastric cancer when multivariate survival analysis was performed.
Conclusions: Our findings indicate that the sex hormone receptors may be partly involved in gastric
carcinogenesis but their clinicopathological and prognostic significance in gastric cancer appears to be limited.
Keywords: Gastric cancer, Estrogen receptor alpha, Estrogen receptor beta, Progesterone receptor,
Androgen receptor, PrognosisBackground
Hormonal therapy is one of the major modalities of sys-
temic treatment for hormone-dependent tumors such as
breast cancer and prostate cancer [1,2]. The principle of
hormonal therapy is that the sex hormones, estrogen or
androgen, stimulate specific hormone-dependent cancer
cells to grow and spread. Deprivation on the synthesis of
such hormones or blocking the hormone signaling path-
ways can induce tumor recession. Particularly, it is well
demonstrated that the hormone receptors are pivotal* Correspondence: jiejunwang@gmail.com; d.wangxi@gmail.com
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reproduction in any medium, provided the ortargets for treatment of hormone-dependent tumors.
Tamoxifen, an estrogen antagonist competitively binding
to estrogen receptor (ER), has obtained great success in
the treatment of ER-positive breast cancer in the past
several decades [1-6]. The success of tamoxifen has
prompted investigators to evaluate the possible role of
hormone receptors in a variety of other tumors derived
from “nontarget” organs and determine the possibility of
hormonal therapy for these tumors, including gastric
cancer [7,8].
Since 1983, a few of studies have examined the expres-
sion of ER in gastric cancer. However, considerable con-
troversy is raised as to the expression level of ER and
its prognostic value in gastric cancer [9-27]. More. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sent in gastric cancer but ER beta (ERβ) is expressed
in abundance, whereas others indicate that the two ER
isoforms are both expressed [22-27]. Furthermore, some
authors find ER expression is correlated with poor differ-
entiation, advanced stage, and adverse outcome while
others suggest the opposite [17,19,23,24,26,27]. Add-
itionally, the roles of progesterone receptor (PR) and
androgen receptor (AR) in gastric cancer are poorly
defined [28]. In the present study, the expression profile
of four sex hormone receptors, ERα, ERβ, PR, and AR,
was determined in gastric tumors and corresponding
normal tissues from a large Chinese cohort, and their
clinicopathological and prognostic value was assessed.Methods
Patients and tissue samples
A total of 1072 patients underwent gastrectomy for
histopathologically confirmed gastric carcinoma in
Changhai Hospital, Second Military Medical University,
Shanghai, China, from 2000 through 2005. Patients with-
out sufficient tissue samples or necessary clinicopatho-
logical information, or patients suffered from double
primary tumors or remnant gastric cancer, or those died
within two months of surgery, were all excluded and
thus 866 eligible patients were enrolled. The patients
were followed up every 6 months until death or study
end (March 30 2010), except for those lost to follow-up.
The tumor tissues and their adjacent normal tissues
from these patients were routinely fixed in 10% buffered
formalin and blocked in paraffin, ready to tissue micro-
array construction. In addition, 60 pairs of fresh gastric
tumors and their matched normal mucosa were
obtained. The fresh tissue samples were prepared care-
fully within 15 min of excision, stabilized in RNAlaterW
solution (Ambion, Austin, TX, USA) at 4°C overnight and
preserved at −20°C until RNA extraction. All patients en-
rolled were naïve for any anticancer therapy. All tissue
specimens were obtained with patient informed consent,
and the protocol was approved by Institutional Review
Board of Second Military Medical University.Total RNA preparation and reverse transcription
Total RNA was extracted from the RNAlaterW-stabilized
tissue samples using an RNAqueousW-4PCR kit (Cat#
AM1914, Ambion, Austin, TX, USA) according to the
manufacturer’s protocol. Complementary DNA (cDNA)
was synthesized from total RNA with use of a High
Capacity cDNA Reverse Transcription Kit (PN4374966,
Applied Biosystems, Foster City, CA), according to the
manufacturer’s instructions. The reaction was incubated
in an ABI 2720 Thermocycler (Applied Biosystems) for
10 min at 25°C, 120 min at 37°C, and 5 min at 85°C.cDNA samples were stored at −20°C before real-time
PCR amplification.
Real-time quantitative PCR
Real-time quantitative PCR was performed with an ABI
PRISMW 7900HT Sequence Detection System (Applied
Biosystems) using the Power SYBRW Green PCR Master
Mix kit (PN4367659, Applied Biosystems) as described
by the manufacturer. A total reaction volume of 50 μl
contained 5 μl of cDNA template corresponding to
100 ng of total RNA, 25 μl of 2 × Power SYBRW Green
PCR Master Mix, 1 μl forward primer of 10 μM, 1 μl
reverse primer of 10 μM and 18 μl ddH2O. Negative
controls included water instead of cDNA in the PCR
reaction and addition of RNA instead of cDNA, and
β-actin was used as an endogenous control. The primer
sequences were as follows: ERα 50-TCCTGATGAT
TGGTCTCGTCT-30 (forward) and 50-ACATTTTCCCT
GGTTCCTGTC-30 (reverse), ERβ 50-AGTCTGGTCGT
GTGAAGGATG-30 (forward) and 50-ACTTCTCTGTC
TCCGCACAAG-30 (reverse), PR 50-ACACCTCCAGTT
CTTTGCTGAC-30 (forward) and 50-ATTCTTTCAT
CCGCTGTTCATT-30 (reverse), AR 50-ATTGTCCAT
CTTGTCGTCTTCG-30 (forward) and 50-AGCCTCTC
CTTCCTCCTGTAGT-30 (reverse), and β-actin 50-TGT
TACAGGAAGTCCCTTGC-30 (forward) and 50-AAGC
AATGCTATCACCTCCC-30 (reverse). All primers were
synthesized by Sangon Biotech Co. Ltd., Shanghai, China.
The amplification was run at 95°C for 10 min followed
by 40 cycles of 95°C for 15 sec and 60°C for 1 min. All
samples were run in triplicate, and data were analyzed by
use of the Sequence Detection System (SDS) Software
Version 2.3 (Applied Biosystems). The specificity of amp-
lification reaction was confirmed by analyzing the corre-
sponding dissociation curves. The quantification of sex
hormone receptors was normalized to β-actin expression
using the 2-ΔΔCt method.
Tissue microarray construction and
immunohistochemistry
Tissue microarrays were constructed from formalin-
fixed and paraffin-embedded archival tissue blocks using
a tissue arrayer (Beecher Instruments, Silver Spring,
MD) according to the previous description [29,30]. For
each of 866 patients, duplicate gastric tumor cylinders
and at least one matched adjacent normal mucosa cylin-
der with a diameter of 1.5 mm were arrayed and con-
secutive 4 μm sections were cut. Immunohistochemistry
assay for ERα, ERβ, PR, and AR was performed using an
UltraSensitive™ SP kit (#9710, Maixin, Fuzhou, China)
according to the manufacturer’s instructions. Briefly, the
tissue microarray sections were deparaffinized in xylene,
rehydrated with graded ethanol, and subjected to antigen
retrieval in citrate buffer (pH 6.0) in a high-pressure
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endogenous peroxide activity with 3% hydrogen perox-
ide, treated with preimmune goat serum to block
nonspecific binding sites, and then incubated with the
primary mouse monoclonal antibodies against ERα
(clone 33, ab2746, Abcam; 1:50), ERβ (clone 14C8,
ab288, Abcam; 1:100), PR (clone PR-AT 4.14, ab2764,
Abcam; 1:100), and AR (clone AR 441, ab9474,
Abcam; 1:200), respectively. After an overnight incuba-
tion at 4°C, the sections were washed and incubated
with a secondary biotinylated anti-mouse/rabbit anti-
body. The immunostaining was visualized with a diami-
nobenzidine detection kit (DAB-0031, Maixin) and then
the sections were counterstained with hematoxylin,
dehydrated, cleared, and coverslipped. Human breast
cancer tissue overexpressing ERα, ERβ, and PR, and
prostate cancer tissue overexpressing AR were used as
positive controls. Sections incubated without primary
antibody were also included in each staining experiment
as negative controls.
Evaluation of immunostaining
Brown cytoplasmic and/or nuclear staining in the gastric
cancer cells or adjacent normal epitheliums was considered
to be positive. The signal was quantified by the Allred
score system which represented the estimated intensity
and proportion of positive-staining cells [31]. A score ≥3
was designated as positive expression and a score of 0 or
2 was regarded as negative. The immunostaining sections
were viewed by two pathologists independently using an
Olympus CX31 microscope (Olympus, Japan).
Statistical analysis
The expression difference of sex hormone receptors
between gastric tumors and corresponding normal tis-
sues was determined by the Wilcoxon matched-pairs
signed-rank test or Chi-square test where appropriate.
Correlations were computed using the Spearman rank
test. The associations between expression of sex hor-
mone receptors and clinicopathological characteristics
were tested using Chi-square test. The probability of sur-
vival was estimated by Kaplan-Meier method and com-
pared by log-rank test. The prognostic role of sex
hormone receptors in gastric cancer was identified using
univariate and multivariate Cox model. All P values were
two-sided and less than 0.05 was considered statistically
significant. Statistical analyses were performed by the
SPSS 15.0 for windows (SPSS, Chicago, IL, USA).
Results
Expression profile of sex hormone receptors in
gastric cancer
Real-time quantitative PCR showed that the mRNAs of
ERα, ERβ, PR and AR were all detected in all 60 pairs ofgastric tumors and their matched normal mucosa.
Furthermore, the mRNA levels of the four receptors in
gastric tumors were all significantly decreased compared
to those in their matched normal mucosa (Figure 1).
Immunohistochemistry assay based on 866 Chinese
patients further demonstrated the expression of ERα,
ERβ, PR and AR proteins. Unlike the typical nuclear
expression in breast and prostate cancer tissues as posi-
tive controls (see Additional file 1: Figure S1), the four
sex hormone receptors all presented a cytoplasmic/
nuclear staining pattern (Figure 2). However, ERα, PR
and AR immunostaining was mainly localized in the
cytoplasm while ERβ immunostaining was ubiquitously
observed in the nucleus for both normal epithelium and
gastric cancer cells (Figure 2). After exclusion of inevalu-
able cases due to tissue loss or inadequate tissue, the
positive rates of ERα, ERβ, PR and AR expression in nor-
mal tissues were 38.3%, 97.3%, 30.5%, and 52.7%, and
the positive rates of the four receptors in gastric tumor
were 12.0%, 91.9%, 23.3%, and 33.0%, respectively. The
protein level of each receptor in gastric tumor was all
significantly lower than that expressed in normal gastric
mucosa (P < 0.001).Correlations among expression of sex hormone receptors
in gastric cancer
Table 1 shows the Spearman correlations among expres-
sion of the four sex hormone receptors on mRNA and
protein levels. Strong correlations of mRNA expression
between ERα and ERβ, ERα and PR, and ERβ and PR
were revealed, while no significant correlations between
AR and the other three receptors were detected. On pro-
tein level, significant correlations were observed in all
pairwise comparison among immunostaining scores of
the four receptors. However, these correlation coeffi-
cients were so small (r < 0.4) that only extremely weak
correlations among the four receptors were found.ERα and AR expression correlates with tumor grade,
Lauren type, and TNM stage of gastric cancer
Possible associations of ERα, ERβ, PR and AR expres-
sion with available clinicopathological characteristics
of 866 gastric cancer patients are presented in Table 2.
The protein expression of ERα and AR was closely asso-
ciated with tumor grade, Lauren type, T classification,
and N classification (P < 0.001), respectively, and conse-
quently correlated with TNM stage (P < 0.001). Import-
antly, positive staining of ERα and AR was more
frequently observed in patients with better differentiated
tumors, intestinal type, and earlier TNM stage. Either
for ERβ or for PR, only correlations between the posi-
tivity and the tumor grade and Lauren type were
noticed (P < 0.05). No significant associations were found
Figure 1 Scatter plots of (A) ERα, (B) ERβ, (C) PR, and (D) AR mRNA levels in gastric tumors and corresponding adjacent normal
mucosa (n = 60). The line indicates the median value. The mRNA levels were normalized to β-actin and statistical differences were determined
using Wilcoxon matched-pairs signed-rank test.
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pathological characteristics.
ERα and AR expression correlates with favorable outcome
in patients with gastric cancer
Table 3 reports the findings from univariate and multi-
variate survival analysis in gastric cancer. Univariate ana-
lysis showed that the significant prognostic factors
included age, tumor size, tumor grade, Lauren type,
T classification, N classification, radical resection, TNM
stage, ERα expression, and AR expression. For ERα-
positive patients, the 5-year survival rate and median
survival were 71.3% (95% CI, 62.5%-80.1%) and
81.5 months (range, 4–121 months), compared with
50.7% (95% CI, 47.0%-54.4%) and 43.0 months (range,
2–123 months) for ERα-negative patients, respectively.
ERα-positive patients had a significantly better outcome
than ERα-negative patients (P < 0.001; Figure 3A). The
expression of ERβ and PR was not associated with the
prognosis of gastric cancer patients (P = 0.568 for ERβ
and P = 0.385 for PR; Figure 3B and 3C). For patients
with AR-positive tumors, the 5-year survival rate was
59.4% (95%, 53.5%-65.3%) with a median survival of
71.0 months (range, 2–123 months), which took signifi-
cant advantage over a 5-year survival rate of 49.7% (95%
CI, 45.6%-53.8%) with a median survival of 40.0 months
(range, 2–123 months) for patients with AR-negative
tumors (P = 0.028; Figure 3D). However, only age,
tumor size, T classification, N classification, and radicalresection were retained in the multivariate Cox model,
as shown in Table 3. The expression of ERα and AR were
not independent prognostic factors for gastric cancer.
Discussion
In the present study, the expression profile and prognos-
tic role of ERα, ERβ, PR, and AR in gastric cancer was
determined in a large Chinese cohort. Our results
showed that the four receptors were all expressed with
decreased abundance in gastric tumors compared to
adjacent normal tissues. All the four receptors were asso-
ciated with high tumor grade and intestinal type, and the
positive expression of ERα and AR also correlated with
early TNM stage and thereby a favorable outcome.
Our findings are inconsistent with a few previous pub-
lications in which ERα, PR and AR were proposed as ad-
verse factors whereas ERβ was deemed beneficial for
gastric cancer patients [19,26-28]. Factually, substantial
disagreement has been observed for several decades with
regard to the expression and role of sex hormone recep-
tors in gastric cancer. The conflicting findings may be
partly attributed to heterogeneity in experimental meth-
ods, positivity criteria, sample size, and patient ethnicity.
In particular, by various methods, the expression levels
of sex hormone receptors even their presence, varies
in a large range in gastric cancer. Furthermore, most
of these investigations usually suffer from very small
sample size and as a result, the conclusions on clinico-
pathological significance of sex hormone receptors in
Figure 2 Representative immunostaining of sex hormone receptors in gastric tumors and corresponding adjacent normal tissues.
Positive staining of (A, E) ERα, (B, F) ERβ, (C, G) PR, and (D, H) AR in normal tissues, and positive staining of (I, M) ERα, (J, N) ERβ, (K, O) PR, and
(L, P) AR in gastric tumors is shown. Original magnification, ×100 for (A) through (D) and (I) through (L); ×400 for (E) through (H) and (M)
through (P).
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failure to distinguish ERβ from ERα in earlier reports
also contributes to conflicting results for ER.
To minimize the above-mentioned limitations, in this
study, the expression of the four receptors was detected
simultaneously at both mRNA and protein levels. More
importantly, a set of tissue microarray containing tumors
and corresponding normal tissues from 866 Chinese
patients was employed. The largest sample size to date
and the high uniformity of experimental conditions prof-
iting from tissue microarray made our results more reli-
able and convincing.Table 1 Correlations among expression of sex hormone
receptors in gastric cancer
Correlation mRNA expression Protein expression
r P† r P†
ERα vs ERβ 0.795 <0.001 0.136 <0.001
ERα vs PR 0.756 <0.001 0.083 0.016
ERα vs AR 0.328 0.437 0.171 <0.001
ERβ vs PR 0.714 <0.001 0.132 <0.001
ERβ vs AR 0.492 0.231 0.329 <0.001
PR vs AR 0.186 0.734 0.098 0.005
ERα, estrogen receptor alpha; ERβ, estrogen receptor beta; PR, progesterone
receptor; AR, androgen receptor; r, Spearman rank correlation coefficients.
†Spearman rank correlation test.Owing to the well establishment in breast cancer, ERs
also are the best-studied sex hormone receptors in gas-
tric cancer. Using a semi-quantitative RT-PCR, ERβ has
shown a more preferential expression pattern than ERα
in both gastric tumors and normal mucosa. Compared
to the expression in normal gastric mucosa, ERα tends
to increase in tumor tissues while ERβ declines [23,24].
With a real-time quantitative PCR, the presence of ERα
and ERβ mRNA in all tumors and normal mucosa
samples was demonstrated in our study. Moreover, the
significant decrease of both ERα and ERβ mRNAs in
tumors compared to in normal tissues was indicated,
similar to the findings in another study from China [26].
Various expression patterns of ERα and ERβ proteins
have been observed by several investigations. By IHC, a
few studies have found no or sporadic staining of ERα in
gastric tumors even in matched normal tissues, while
strong ERβ staining in both cancer and their non-
cancerous tissues [22,24,27,28]. Our results are not quite
similar to these findings. ERα protein is indeed
expressed in both normal mucosa (38.3%) and gastric
tumors (12.0%) but with a very weak pattern, while ERβ
protein is the predominant isoform of ER in both nor-
mal (97.3%) and cancerous (91.9%) tissues. Both ERα
and ERβ proteins present a decreased expression pattern
in gastric tumors compared to their corresponding
normal tissues [26].





ERα (n = 848) ERβ (n = 823) PR (n = 851) AR (n = 843)
Positive No. (%) P‡ Positive No. (%) P‡ Positive No. (%) P‡ Positive No. (%) P‡
Sex 0.496 0.166 0.522 0.313
Female 261 29 (10.9) 221 (89.8) 58 (21.9) 81 (30.6)
Male 605 73 (12.5) 535 (92.7) 140 (23.9) 197 (34.1)
Age, years 0.837 0.187 0.523 0.254
≤40 70 6 (8.8) 57 (87.7) 12 (17.6) 16 (24.2)
≤50 148 19 (13.2) 126 (93.3) 30 (20.7) 46 (32.2)
≤65 328 39 (12.0) 283 (90.1) 79 (24.5) 102 (31.9)
>65 320 38 (12.2) 290 (93.9) 77 (24.4) 114 (36.3)
Tumor site§ 0.839 0.700 0.433 0.605
Upper 138 19 (13.8) 123 (91.8) 25 (18.2) 52 (38.0)
Middle 263 30 (11.8) 224 (90.3) 63 (24.3) 81 (31.9)
Lower 416 46 (11.3) 368 (92.9) 100 (24.6) 129 (32.0)
Diffuse 49 7 (14.3) 41 (91.1) 10 (20.4) 16 (32.7)
Tumor size, cm 0.166 0.316 0.425 0.127
≤2 133 22 (17.1) 117 (95.9) 28 (22.0) 52 (42.3)
≤3 160 21 (13.7) 134 (89.9) 29 (18.6) 50 (32.3)
≤5 273 30 (11.1) 243 (91.7) 67 (24.7) 84 (31.3)
>5 300 29 (9.8) 262 (91.3) 74 (24.9) 92 (31.0)
Tumor grade <0.001 0.030 0.001 <0.001
Well 48 15 (31.9) 53 (96.4) 19 (40.4) 22 (48.9)
Moderate 286 47 (16.5) 274 (94.5) 77 (27.1) 127 (44.9)
Poor 532 40 (7.8) 429 (89.7) 102 (19.6) 129 (25.0)
Lauren type 0.012 0.010 0.017 <0.001
Intestinal 535 76 (14.4) 481 (93.0) 139 (26.3) 197 (37.6)
Diffuse 297 21 (7.4) 250 (91.2) 55 (19.0) 68 (23.9)
Mixed 34 5 (14.7) 25 (78.1) 4 (11.8) 13 (38.2)
T classification¶ <0.001 0.195 0.818 <0.001
pT1 132 33 (26.0) 114 (95.0) 28 (21.7) 61 (48.8)
pT2 142 19 (13.9) 125 (94.7) 36 (26.3) 49 (36.6)
pT3 528 44 (8.4) 463 (90.8) 120 (23.0) 147 (28.2)
pT4 64 6 (9.7) 54 (88.5) 14 (22.2) 21 (33.9)
N classification¶ <0.001 0.574 0.340 0.001
pN0 309 67 (22.3) 272 (93.2) 76 (25.0) 125 (41.9)
pN1 314 20 (6.5) 275 (90.2) 63 (20.7) 85 (28.0)
pN2 191 13 (6.9) 165 (92.7) 43 (22.6) 52 (27.4)
pN3 52 2 (3.9) 44 (91.7) 16 (30.8) 16 (31.4)
TNM stage¶ <0.001 0.173 0.535 <0.001
I 187 44 (24.4) 165 (95.4) 48 (26.2) 85 (47.8)
II 158 21 (13.5) 138 (90.8) 39 (25.3) 53 (35.1)
III 294 23 (8.0) 253 (89.7) 61 (21.0) 74 (25.3)
IV 227 14 (6.3) 200 (92.6) 50 (22.3) 66 (29.7)
ERα, estrogen receptor alpha; ERβ, estrogen receptor beta; PR, progesterone receptor; AR, androgen receptor. †Total patients except for inevaluable cases due to
tissue loss or inadequate tissue in immunohistochemistry assay. ‡Chi-square test. §Japanese Classification of Gastric Carcinoma (3rd English edition) proposed by
the Japanese Gastric Cancer Association (JGCA). ¶The 6th TNM Classification of Malignant Tumors proposed by the AJCC/UICC.
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Table 3 Univariate and multivariate analysis of overall survival by Cox model in gastric cancer
Variable Univariate cox Multivariate cox
HR 95% CI P HR 95% CI P
Sex: female vs male 0.896 0.728-1.103 0.302
Age, years: ≤40 vs ≤50 vs ≤65 vs >65 1.262 1.127-1.412 <0.001 1.226 1.089-1.379 0.001
Tumor site: upper vs middle vs lower vs diffuse† 0.998 0.883-1.128 0.976
Tumor size, cm: ≤2 vs ≤3 vs ≤5 vs >5 1.590 1.434-1.764 <0.001 1.149 1.023-1.291 0.019
Tumor grade: well vs moderate vs poor 1.540 1.287-1.841 <0.001 1.191 0.959-1.481 0.114
Lauren type: intestinal vs diffuse vs mixed 1.202 1.020-1.415 0.028 1.143 0.945-1.383 0.167
T classification: pT1 vs pT2 vs pT3 vs pT4‡ 2.135 1.859-2.451 <0.001 1.490 1.263-1.757 <0.001
N classification: pN0 vs pN1 vs pN2 vs pN3‡ 2.237 2.017-2.481 <0.001 1.733 1.543-1.947 <0.001
Radical resection: yes vs no 3.337 2.706-4.114 <0.001 2.053 1.641-2.570 <0.001
TNM stage: I vs II vs III vs IV‡§ 2.306 2.064-2.576 <0.001
ERα: positive vs negative 1.990 1.380-2.871 <0.001 1.159 0.797-1.685 0.441
ERβ: positive vs negative 1.107 0.779-1.573 0.572
PR: positive vs negative 0.905 0.723-1.135 0.389
AR: positive vs negative 1.265 1.023-1.564 0.030 1.072 0.858-1.340 0.541
HR, hazard ratio; CI, confidence interval; ERα, estrogen receptor alpha; ERβ, estrogen receptor beta; PR, progesterone receptor; AR, androgen receptor. †Japanese
Classification of Gastric Carcinoma (3rd English edition) proposed by the Japanese Gastric Cancer Association (JGCA). ‡The 6th TNM Classification of Malignant
Tumors proposed by the AJCC/UICC. §TNM stage was not included into multivariate Cox model to avoid repetition with T and N classifications.
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early as ER, and the positive expression of PR ranges
from none to all [9,10,12-21]. As far as AR is concerned,
very little attention has been paid to AR in gastric can-
cer. Following the first detection of AR in 2 of 16 gastric
cancer patients, a positive rate of 17.4% for AR nuclear
staining in an immunohistochemical study of 86 cases
was indicated [12,28]. In the present study, our results
show a positive rate of 30.5% in normal mucosa and
23.3% in gastric tumors for PR, and 52.7% in normal
tissues and 33.0% in tumors for AR.
When the localization of the four sex hormone recep-
tors is concerned, a few earlier studies have revealed that
they were solely expressed in the nuclei of gastric cancer
cells [22,28]. However, a few recent studies also reported
a cytoplasmic staining of ERα and a cytoplasmic/nuclear
staining of ERβ in gastric cancer [26,27]. In the present
study, unlike the typical nuclear expression in breast
and prostate cancer tissues as positive controls (see
Additional file 1: Figure S1), the four sex hormone
receptors all presented a cytoplasmic/nuclear staining
pattern (Figure 2). Particularly, ERα, PR and AR immu-
nostaining was mainly localized in the cytoplasm while
ERβ immunostaining was mostly detected in the nuclei.
Although our findings provided added information
to the localization of sex hormone receptors in gastric
cancer, agreement on the immunostaining location could
not be finalized yet. Factually, the immunostaining
location might be affected by the characteristics of
antibody to some extent. In particular, different antibodiesobtained from various clones usually result in inconsistent
findings. For example, a sole nuclear immunostaining of
ERα was observed with a mouse monoclonal antibody
(clone ER88) [28] while a cytoplasmic expression pattern
of ERα was detected with another mouse monoclonal
antibody (clone 1D5) [26]. For ERβ, a sole nuclear
expression was noticed with the use of a mouse mono-
clonal antibody (clone 14C8) [26] while with another
mouse monoclonal antibody (clone PPG5/10), a cyto-
plasmic/nuclear expression was identified [27]. There-
fore, it would be ideal to examine the immunostaining of
the four sex hormone receptors synchronously by using
a wide panel of antibodies obtained from various clones
as many as possible. In the present study, only a single
antibody for each receptor was used and the absence of
other antibodies produced from various clones was the
main limitation.
Nevertheless, based on the currently available evi-
dence, the nuclear and cytoplasmic immunostaining pat-
terns might indicate two different functional forms of
sex hormone receptors in gastric cancer which were pre-
sumed to be dependent on the specific status of cancer
cells. Seeing that the cytoplasmic expression of ERα and
ERβ has also been observed in non-small cell lung can-
cer [32,33], the cytoplasmic expression of sex hormone
receptors in these tumors derived from “nontarget”
organs might suggest an independent or a novel mech-
anism involving in tumorigenesis distinct from the
genomic signaling via nuclear forms typically occurred
in breast cancer [33]. Certainly, more studies by use of
Figure 3 Kaplan-Meier survival curves according to (A) ERα, (B) ERβ, (C) PR, and (D) AR immunostaining (log-rank test).
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techniques are warranted to carefully verify all of these
assumptions in the future.
The associations between sex hormone receptors and
clinicopathological factors of gastric tumors have been
studied extensively. One of the most concerns is the ex-
pression difference of sex hormone receptors in both
genders which might be a possible interpretation of male
predominance among gastric cancer patients [34]. How-
ever, no significant difference is found between male and
female patients in this study though slight higher posi-
tive rates in male patients are observed (Table 2), which
suggested that the sex difference of gastric cancer
incidence cannot attributed to sex hormone receptors
at least.
In this study, the expression of four hormone recep-
tors is all closely associated with tumor grade and Lau-
ren type. Moreover, the positive immunostaining always
indicates a high tumor differentiation and intestinal type
(Table 2), and the positive rates of the four receptors innormal tissues are always significantly higher than that
in corresponding tumors. Given sex hormone receptors
are critical effectors of normal cell growth and differenti-
ation, it is logical to assume that these receptors are also
involved in the physiological maintenance of differenti-
ation and function of gastric mucosa [35]. Together with
the findings that sex hormone-receptor-negative tumors
have a higher proliferative activity than sex hormone-
receptor-positive tumors in human gastrointestinal tract
adenocarcinomas [16], the abnormal expression or func-
tion of these receptors may be implicated in the patho-
genesis of gastric cancer to some extent [5-7].
Besides tumor grade and Lauren type, the positivity of
ERα and AR proteins also negatively correlates with
advanced T and N classifications, and thereby correlates
with an early TNM stage significantly (Table 2). Just as
we expected, positive expression of ERα and AR corre-
lates with favorable outcome for gastric cancer patients
though they are not independent prognostic factors
(Table 3). When ERβ and PR are concerned, no
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sion and any clinicopathological characteristics except
for tumor grade and Lauren type. Under this circum-
stance, the prognostic importance of ERβ and PR in
gastric cancer is weak. In fact, so do our findings in the
present study.
Conclusion
Our results confirmed the presence of ERα, ERβ, PR,
and AR in both gastric tumors and normal mucosa but
their expression levels were extremely low except for the
predominance of ERβ. The decreased expression pattern
of the four receptors in gastric tumors and their associa-
tions with clinicopathological characteristics as well as
overall survival indicate that the sex hormone receptors
may be partly involved in gastric carcinogenesis. To-
gether with the independent expression of the four
receptors (Table 1) and the failure of hormone therapy
for gastric cancer [36], the function and significance
of sex hormone receptors in gastric cancer appears to
be limited.
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tissue is shown. Original magnification, × 400.
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